Gemcitabine is an antimetabolites, which inhibits DNA synthesis with an IC50 of 0.06 µM. Gemcitabine is a nucleoside analogue that is incorporated into replicating DNA, resulting in partial chain termination and stalling of replication forks.
|Cell lines||BxPC-3, PANC-1 and PaCa-2 cell lines|
|Preparation method||Cell Counts. The cells were plated in 6-well plates. Twenty-four hours later, the cells were treated with vehicle, gemcitabine, DMAPT, or the combination. After 72 h of treatment, trypan blue-excluded cell counts were performed in duplicate using a hemocytometer. Cell growth was expressed relative to vehicle-treated cells (100 %).|
|Concentrations||0, 0.005, 0.01, 0.02, 0.04 μM|
|Incubation time||72 h|
|Animal models||MIA PaCa-2 Xenografts model in athymic nude mice|
|Formulation||phosphate-buffered saline, PBS|
|Dosages||a single dose of 50 or 100 mg/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.
Rich et al. Onco Targets Ther. 2012;5:161-70. PMID: 22977306.
Enhancement Of The Antiproliferative Activity Of Gemcitabine By Modulation Of C-Met Pathway In Pancreatic Cancer.
Avan et al. Curr Pharm Des. 2012 Sep 7. PMID: 22973962.
Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.
Tajima et al. Exp Ther Med. 2012 May;3(5):787-792. PMID: 22969969.
Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.
Kasuya et al. Exp Ther Med. 2012 Apr;3(4):599-602. PMID: 22969935.
Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK, et al. J Gastrointest Surg. 2012 Jul;16(7):1333-40. PMID: 22618517.
|Related Checkpoint Products|
CCT241533 hydrochloride is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM.
CCT241533 is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM.
BML-277 is a high efficient Chk2 inhibitors, IC50 is 15 nM.
AZD7762 hydrochloride is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.
CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.